Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | CDK11B | P21127 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | CDKL2 | Q92772 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 3/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 3/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | FLT4 | P35916 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12336250 | 0.92 | PDGFRB (0.61) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336258 | 0.92 | PDGFRB (0.62) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL14949362 | 0.90 | PDGFRB (0.40) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336540 | 0.88 | PDGFRB (0.42) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336569 | 0.87 | PDGFRB (0.47) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336270 | 0.87 | PDGFRB (0.47) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL14949588 | 0.86 | PDGFRB (0.45) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336580 | 0.85 | MAPT (0.47) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12348796 | 0.85 | PDGFRB (0.61) | PDGFRBKITPDGFRACDK11BFLT3 | |
| SCHEMBL12336419 | 0.85 | PDGFRB (0.44) | PDGFRBKITPDGFRACDK11BFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9212151-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212151-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-8957216-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957216-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS INC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS INC (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2011119894-A2 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | KINAGEN, INC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | MAP4K2, MAP3K20, MAP3K19 | PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885 |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885 |
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.